Trial · NCT07883642
Traditional Chinese Medicine Treatment for Capecitabine-Related Hand-Foot Syndrome
NCT07883642, Early phase 1, Not yet recruiting, Emeishan Hospital of Traditional Chinese Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Traditional Chinese Medicine Treatment for Capecitabine-Related Hand-Foot Syndrome. Trials, record NCT07883642. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07883642
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Traditional Chinese Medicine Treatment for Capecitabine-Related Hand-Foot Syndrome
- NCT number
- NCT07883642
- Status
- Not yet recruiting
- Phases
- Early phase 1
- Enrollment
- 7 participants, estimated
- Lead sponsor
- Emeishan Hospital of Traditional Chinese Medicine
- Conditions
- Palmar and Plantar Erythema, Numbness of the Four Limbs, Pain in the Distal Extremities, Peeling of the Soles and Palms
- Interventions
- Twelve-Ingredient Prepared Sichuan Aconite Hand and Foot Bath, Standard Basic Nursing Interventions
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hand-Foot Syndrome Grading | on the day of enrollment, at week 1, at week 3, and on day 7 after completion of the intervention | Grade 1: Numbness, paresthesia, or tingling in the hands and feet. Grade 2: Discomfort in holding objects or walking; painless swelling or erythema. Grade 3: Painful erythema, edema of the palms and soles, periungual erythema, and swelling. Grade 4: Desquamation, ulceration, blistering, and severe pain. |
| Secondary | numeric rating scale (NRS) score | on the day of enrollment, at week 1, at week 3, and on day 7 after completion of the intervention | The NRS (Numeric Rating Scale) is a simple tool used to assess pain intensity, usually scored from 0 to 10, where 0 indicates no pain and 10 indicates the worst possible pain. |
| Secondary | capecitabine dose maintenance rate | on the day of enrollment, at week 1, at week 3, and on day 7 after completion of the intervention | capecitabine dose maintenance rate during the 3-week observation period |
| Secondary | Quality of life score (EORTC QLQ-C30) | on the day of enrollment, at week 1, at week 3, and on day 7 after completion of the intervention |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07883642
GET https://conductscience.org/api/trials/v1/NCT07883642/registered